Not currently recruiting at University of California Health

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

a study on Breast Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by Rena D. Callahan, MD (ucla)
Headshot of Rena D. Callahan
Rena D. Callahan

Description

Summary

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

Official Title

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

Details

This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant combined with a CDK4/6 inhibitor (Investigator's choice of palbociclib or ribociclib) for the treatment of patients with advanced (inoperable) or metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer whose disease has progressed during or within 12 months of adjuvant treatment with endocrine therapy (either an AI or tamoxifen), and who have not received prior systemic therapy for ABC. Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib is a CDK4/6 inhibitor. Fulvestrant is a selective estrogen receptor degrader (SERD). Following completion of the safety run-in phase to determine the gedatolisib dose with ribociclib, subjects will be assigned to 1 of 2 cohorts based on their PIK3CA status and then randomized to either the investigational treatment arm (gedatolisib with fulvestrant and ribociclib or palbociclib) or standard-of-care control arm (fulvestrant and ribociclib or palbociclib).

Keywords

Breast Cancer, Breast Cancer, Advanced or Metastatic, Gedatolisib, HR Positive, ER Positive, HER2 Negative, PIK3CA MT, PI3K, Breast Neoplasms, Neoplasm Metastasis, palbociclib, ribociclib, Fulvestrant, Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant, Arm B: Palbociclib or Ribociclib + Fulvestrant

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced HR+/HER2- breast cancer
  2. Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue for the duration of the study.
  3. Negative pregnancy test for females of childbearing potential. Female subjects who are not surgically sterile must use a medically effective contraceptive method from screening until 2 years after the last dose of study treatment.
  4. Progression of disease during or within 12 months of completing (neo)adjuvant ET.
  5. Adequate archival, fresh tumor tissue, or liquid biopsy for the analysis of PIK3CA mutational status.
  6. Permitted prior therapies:
    1. (neo)adjuvant fulvestrant or any selective ER degrader only if the treatment duration < 6 months
    2. (neo)adjuvant chemotherapy
    3. (neo)adjuvant CDK4/6 inhibitor, unless PD was on or within 6 months of discontinuation of CDK4/6i
  7. Subject has radiologically measurable disease according to RECIST v1.1, per local assessment. Patients with evaluable bone-only disease are not eligible. Patients with bone-only disease that has lytic or mixed lytic/blastic lesions and at least one measurable soft tissue component per RECIST v1.1 may be eligible.
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  9. Life expectancy of at least >6 months.
  10. Adequate bone marrow, hepatic, renal and coagulation function.

You CAN'T join if...

  1. Concurrent malignancies other than adequately treated non-melanoma skin cancer. Previous malignancies in remission but curatively treated with no evidence of disease progression and judged by local Investigator to be at low risk of impacting health or survival while on study.
  2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor
  3. Prior treatment with systemic anticancer therapy for ABC
  4. Subjects with type 1 diabetes
  5. Known and untreated, or active, brain or leptomeningeal metastases
  6. History of clinically significant cardiovascular abnormalities
  7. History of drug-induced symptomatic interstitial lung disease (pneumonitis) or hepatitis

Locations

  • UCLA Hematology Oncology Ventura not yet accepting patients
    Los Angeles 5368361 California 5332921 93003 United States
  • Providence Medical Foundation not yet accepting patients
    Fullerton 5351247 California 5332921 92835 United States
  • Mercy Health-Paducah Cancer Center accepting new patients
    Paducah 4048662 Kentucky 6254925 42003 United States
  • American Oncology Partners, P.A. accepting new patients
    Bethesda 4348599 Maryland 4361885 20817 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Celcuity Inc
ID
NCT06757634
Phase
Phase 3 Breast Cancer Research Study
Study Type
Interventional
Participants
Expecting 674 study participants
Last Updated